Summary Text

SUMMARY: First diagnosed with myeloma October 2011. Recruited onto clinical trial Myeloma X11 (Lenalidomide) at Bristol Oncology and Haematology Centre. First High Dose Therapy and Stem Cell Transplant (HDT&SCT) in July 2012. On maintenance until June 2017. June 2018 recruited onto Myeloma XII trial (Ixazomib). December 2018 Second HDT&SCT. On maintenance until February 2020. August 2020 Commenced treatment involving Daratumumab. April 2021 relapsed. June 2021 recruited onto Cartitude 4 clinical trial and infused with CAR-T cells in October 2021. My own immune system is now fighting the cancer . I am exceedingly fortunate.


Sunday, 2 August 2020

Update 2nd August

Early this week I had a phone call from my nurse specialist who now had my paraprotein result.  It was rather higher than anticipated and represented an increase in the rate of change.  We discussed my options and preferences for future treatment which she agreed to discuss at the Multi-disciplinary Team meeting.  After the meeting she again phoned me to say that although final decisions needed to be made, my preferences had been agreed to.  Very positively, she would be booking outpatient treatment appointments.  She would also be arranging a face meeting mid August at which I will sign the necessary consents.

Although this has not been the best news, it is by no means unexpected.

Keep safe, keep well

Stephen